Under a new co-exclusive agreement, Thermo Fisher will be able to sell 908's ZipChip platform alongside its HRAM mass spec instruments.
The agreement lets Biotheranostics offer its CancerType ID and Breast Cancer Index genomic tests to customers through Syapse's software.
The companies will combine Dovetail's genome assembly services with PacBio's SMRT sequencing and de novo assembly tools.
The agreement will allow Rubicon offer Curio's software as a commercial bioinformatics solution for its ThruPlex Tag-seq library preparation kits.
The companies will co-promote Dovetail's in vitro proximity ligation-based libraries specifically prepared for Illumina sequencing platforms.
The co-marketing arrangement will initially cover hospitals and laboratories in Europe, the Middle East, and Africa.
BGI has signed an agreement to offer NRGene's bioinformatics tools as part of its agricultural genomic analysis service to customers in Asia.
The planned solution will enable secondary and tertiary analysis and visualization of single-cell sequence data.
ArcherDx has signed separate agreements to integrate its target enrichment assays with PierianDx's software and with MPLN's oncology testing services.
ArcherDx will continue to sell its FusionPlex assays directly in the US market, while Illumina has gained non-exclusive rights to market and sell them worldwide.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.